Rongqiang Yang1,2, Steven W Li1,2,3, Zirong Chen1,2, Xin Zhou1,2, Wei Ni1,4, Dongtao A Fu5, Jianrong Lu1,2,6, Frederic J Kaye2,3, Lizi Wu1,2,4. 1. Department of Molecular Genetics and Microbiology. 2. UF Health Cancer Center. 3. Department of Medicine. 4. UF Genetics Institute. 5. Department of Pathology, Immunology and Laboratory Medicine. 6. Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, FL.
Abstract
BACKGROUND: The LKB1 tumor suppressor gene is commonly inactivated in non-small cell lung carcinomas (NSCLC), a major form of lung cancer. Targeted therapies for LKB1-inactivated lung cancer are currently unavailable. Identification of critical signaling components downstream of LKB1 inactivation has the potential to uncover rational therapeutic targets. Here we investigated the role of INSL4, a member of the insulin/IGF/relaxin superfamily, in LKB1-inactivated NSCLCs. METHODS: INSL4 expression was analyzed using global transcriptome profiling, quantitative reverse transcription PCR, western blotting, enzyme-linked immunosorbent assay, and RNA in situ hybridization in human NSCLC cell lines and tumor specimens. INSL4 gene expression and clinical data from The Cancer Genome Atlas lung adenocarcinomas (n = 515) were analyzed using log-rank and Fisher exact tests. INSL4 functions were studied using short hairpin RNA (shRNA) knockdown, overexpression, transcriptome profiling, cell growth, and survival assays in vitro and in vivo. All statistical tests were two-sided. RESULTS: INSL4 was identified as a novel downstream target of LKB1 deficiency and its expression was induced through aberrant CRTC-CREB activation. INSL4 was highly induced in LKB1-deficient NSCLC cells (up to 543-fold) and 9 of 41 primary tumors, although undetectable in all normal tissues except the placenta. Lung adenocarcinomas from The Cancer Genome Atlas with high and low INSL4 expression (with the top 10th percentile as cutoff) showed statistically significant differences for advanced tumor stage (P < .001), lymph node metastasis (P = .001), and tumor size (P = .01). The INSL4-high group showed worse survival than the INSL4-low group (P < .001). Sustained INSL4 expression was required for the growth and viability of LKB1-inactivated NSCLC cells in vitro and in a mouse xenograft model (n = 5 mice per group). Expression profiling revealed INSL4 as a critical regulator of cell cycle, growth, and survival. CONCLUSIONS: LKB1 deficiency induces an autocrine INSL4 signaling that critically supports the growth and survival of lung cancer cells. Therefore, aberrant INSL4 signaling is a promising therapeutic target for LKB1-deficient lung cancers.
BACKGROUND: The LKB1tumor suppressor gene is commonly inactivated in non-small cell lung carcinomas (NSCLC), a major form of lung cancer. Targeted therapies for LKB1-inactivated lung cancer are currently unavailable. Identification of critical signaling components downstream of LKB1 inactivation has the potential to uncover rational therapeutic targets. Here we investigated the role of INSL4, a member of the insulin/IGF/relaxin superfamily, in LKB1-inactivated NSCLCs. METHODS:INSL4 expression was analyzed using global transcriptome profiling, quantitative reverse transcription PCR, western blotting, enzyme-linked immunosorbent assay, and RNA in situ hybridization in humanNSCLC cell lines and tumor specimens. INSL4 gene expression and clinical data from The Cancer Genome Atlas lung adenocarcinomas (n = 515) were analyzed using log-rank and Fisher exact tests. INSL4 functions were studied using short hairpin RNA (shRNA) knockdown, overexpression, transcriptome profiling, cell growth, and survival assays in vitro and in vivo. All statistical tests were two-sided. RESULTS:INSL4 was identified as a novel downstream target of LKB1 deficiency and its expression was induced through aberrant CRTC-CREB activation. INSL4 was highly induced in LKB1-deficient NSCLC cells (up to 543-fold) and 9 of 41 primary tumors, although undetectable in all normal tissues except the placenta. Lung adenocarcinomas from The Cancer Genome Atlas with high and low INSL4 expression (with the top 10th percentile as cutoff) showed statistically significant differences for advanced tumor stage (P < .001), lymph node metastasis (P = .001), and tumor size (P = .01). The INSL4-high group showed worse survival than the INSL4-low group (P < .001). Sustained INSL4 expression was required for the growth and viability of LKB1-inactivated NSCLC cells in vitro and in a mouse xenograft model (n = 5 mice per group). Expression profiling revealed INSL4 as a critical regulator of cell cycle, growth, and survival. CONCLUSIONS:LKB1 deficiency induces an autocrine INSL4 signaling that critically supports the growth and survival of lung cancer cells. Therefore, aberrant INSL4 signaling is a promising therapeutic target for LKB1-deficient lung cancers.
Authors: B Brandt; D Kemming; J Packeisen; R Simon; M Helms; U Feldmann; A Matuschek; C Kersting; B Hinrichs; J-M Bidart; D Bellet; K Bartkowiak; N Dankbar; T Dittmar; G Sauter; W Boecker; H Buerger Journal: Endocr Relat Cancer Date: 2005-12 Impact factor: 5.678
Authors: Müge Çeliktas; Ichidai Tanaka; Satyendra Chandra Tripathi; Johannes F Fahrmann; Clemente Aguilar-Bonavides; Pamela Villalobos; Oliver Delgado; Dilsher Dhillon; Jennifer B Dennison; Edwin J Ostrin; Hong Wang; Carmen Behrens; Kim-Anh Do; Adi F Gazdar; Samir M Hanash; Ayumu Taguchi Journal: J Natl Cancer Inst Date: 2017-03-01 Impact factor: 13.506
Authors: Chunxia Cao; Ruli Gao; Min Zhang; Antonio L Amelio; Mohammad Fallahi; Zirong Chen; Yumei Gu; Chengbin Hu; Eric A Welsh; Brienne E Engel; Eric B Haura; W Douglas Cress; Lizi Wu; Maria Zajac-Kaye; Frederic J Kaye Journal: J Natl Cancer Inst Date: 2014-12-01 Impact factor: 13.506
Authors: Jérôme Boudeau; Annette F Baas; Maria Deak; Nick A Morrice; Agnieszka Kieloch; Mike Schutkowski; Alan R Prescott; Hans C Clevers; Dario R Alessi Journal: EMBO J Date: 2003-10-01 Impact factor: 11.598
Authors: Yan Liu; Kevin Marks; Glenn S Cowley; Julian Carretero; Qingsong Liu; Thomas J F Nieland; Chunxiao Xu; Travis J Cohoon; Peng Gao; Yong Zhang; Zhao Chen; Abigail B Altabef; Jeremy H Tchaicha; Xiaoxu Wang; Sung Choe; Edward M Driggers; Jianming Zhang; Sean T Bailey; Norman E Sharpless; D Neil Hayes; Nirali M Patel; Pasi A Janne; Nabeel Bardeesy; Jeffrey A Engelman; Brendan D Manning; Reuben J Shaw; John M Asara; Ralph Scully; Alec Kimmelman; Lauren A Byers; Don L Gibbons; Ignacio I Wistuba; John V Heymach; David J Kwiatkowski; William Y Kim; Andrew L Kung; Nathanael S Gray; David E Root; Lewis C Cantley; Kwok-Kin Wong Journal: Cancer Discov Date: 2013-05-28 Impact factor: 39.397
Authors: J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson Journal: Science Date: 2004-04-29 Impact factor: 47.728
Authors: F M Giardiello; S B Welsh; S R Hamilton; G J Offerhaus; A M Gittelsohn; S V Booker; A J Krush; J H Yardley; G D Luk Journal: N Engl J Med Date: 1987-06-11 Impact factor: 91.245
Authors: Li Ding; Gad Getz; David A Wheeler; Elaine R Mardis; Michael D McLellan; Kristian Cibulskis; Carrie Sougnez; Heidi Greulich; Donna M Muzny; Margaret B Morgan; Lucinda Fulton; Robert S Fulton; Qunyuan Zhang; Michael C Wendl; Michael S Lawrence; David E Larson; Ken Chen; David J Dooling; Aniko Sabo; Alicia C Hawes; Hua Shen; Shalini N Jhangiani; Lora R Lewis; Otis Hall; Yiming Zhu; Tittu Mathew; Yanru Ren; Jiqiang Yao; Steven E Scherer; Kerstin Clerc; Ginger A Metcalf; Brian Ng; Aleksandar Milosavljevic; Manuel L Gonzalez-Garay; John R Osborne; Rick Meyer; Xiaoqi Shi; Yuzhu Tang; Daniel C Koboldt; Ling Lin; Rachel Abbott; Tracie L Miner; Craig Pohl; Ginger Fewell; Carrie Haipek; Heather Schmidt; Brian H Dunford-Shore; Aldi Kraja; Seth D Crosby; Christopher S Sawyer; Tammi Vickery; Sacha Sander; Jody Robinson; Wendy Winckler; Jennifer Baldwin; Lucian R Chirieac; Amit Dutt; Tim Fennell; Megan Hanna; Bruce E Johnson; Robert C Onofrio; Roman K Thomas; Giovanni Tonon; Barbara A Weir; Xiaojun Zhao; Liuda Ziaugra; Michael C Zody; Thomas Giordano; Mark B Orringer; Jack A Roth; Margaret R Spitz; Ignacio I Wistuba; Bradley Ozenberger; Peter J Good; Andrew C Chang; David G Beer; Mark A Watson; Marc Ladanyi; Stephen Broderick; Akihiko Yoshizawa; William D Travis; William Pao; Michael A Province; George M Weinstock; Harold E Varmus; Stacey B Gabriel; Eric S Lander; Richard A Gibbs; Matthew Meyerson; Richard K Wilson Journal: Nature Date: 2008-10-23 Impact factor: 49.962
Authors: Linn Fagerberg; Björn M Hallström; Per Oksvold; Caroline Kampf; Dijana Djureinovic; Jacob Odeberg; Masato Habuka; Simin Tahmasebpoor; Angelika Danielsson; Karolina Edlund; Anna Asplund; Evelina Sjöstedt; Emma Lundberg; Cristina Al-Khalili Szigyarto; Marie Skogs; Jenny Ottosson Takanen; Holger Berling; Hanna Tegel; Jan Mulder; Peter Nilsson; Jochen M Schwenk; Cecilia Lindskog; Frida Danielsson; Adil Mardinoglu; Asa Sivertsson; Kalle von Feilitzen; Mattias Forsberg; Martin Zwahlen; IngMarie Olsson; Sanjay Navani; Mikael Huss; Jens Nielsen; Fredrik Ponten; Mathias Uhlén Journal: Mol Cell Proteomics Date: 2013-12-05 Impact factor: 5.911